He rongoā pūtau-autologous te GT101 i hangaia mai i te TIL kua whakawhānuihia, kua whakahoutia mai i te pukupuku o te tūroro. Ka tukuna te rongoā mā te hauhake i te kiko pukupuku mai i ngā tūroro me te tango i te TIL. Kātahi ka whakanuia te TIL kua tangohia mā te whakamahi i te tūāpapa hanga motuhake a Grit Bio, a StemTexp®, ka whakahokia ki roto i ngā tūroro hei whawhai i ngā pukupuku.
I te tau 2024Hui-ā-Tau a te Rōpū Amerikana mō te Matepukupuku Hauora (ASCO),i ripoatahia ngā raraunga mō ngā tūroro pukupuku totoka 14 i uru ki te rangahau GT101. I hangaia te whakamātautau me te whāinga matua ki te aromatawai i te DLT me te whakaahua i te kōtaha haumaru o GT101 i roto i ngā tūroro pukupuku totoka i inehia e te auau o ngā pānga kino ohorere o te maimoatanga (TEAE) o te Tau ≥ 3. Ko ngā whāinga tuarua he aromatawai i ngā tawhā whai huatanga tae atu ki te tere urupare whānui (ORR), te tere whakahaere mate (DCR), te oranga kore-haere (PFS), te roa o te urupare (DOR), me te oranga whānui (OS) e ai ki te RECIST v1.1.
Ngā Hua: I te 10 o Noema, 2023, i whiwhi maimoatanga te rōpū o ngā tūroro 14, ko te tau toharite he 46.9, ā, ko te tau toharite he 2.6 ngā raina o ngā maimoatanga o mua. Whai muri i te lymphodepletion paerewa e hangai ana ki te FC, i werohia ngā tūroro ki te GT101 i ngā horopeta ≥ 5×109 pūtau me te horopeta toharite he 3.7×1010 pūtau, ā, i muri mai ko te whakahaere IL-2 horopeta teitei. Ko te nuinga o ngā AE Taumata ≥ 3 i kitea i hono atu ki te tikanga whakatikatika FC me te IL-2, tae atu ki te hekenga o te maha o ngā lymphocyte, te hekenga o te maha o ngā pūtau toto mā, te hekenga o te maha o ngā neutrophil, te anemia, te pyrexia me te hekenga o te maha o ngā platelet. Ko te nuinga o ēnei AE i ora i roto i ngā rā 14, ko ētahi i heke iho ki te ≤ Taumata 2 i roto i ngā wiki 4. I roto i ngā tūroro 14 i whakaurua puta noa i ngā tohu rerekē (matepukupuku pūtau-iti-pūkahukahu, melanoma, matepukupuku waha), ko te ORR he 35.7%. Ina koa, e 4 ngā tohu (28.6%) i whakamanahia he urupare ā-wāhanga (PR), 1 te tohu (7.1%) i tutuki i te urupare katoa (CR), ā, e 8 ngā tohu (57.1%) i whakamanahia he mate pumau (SD) hei urupare pai. Kotahi te tohu i kore i whakamanahia te ahunga whakamua o te mate (PD). He mea nui, i roto i te 11/14 o ngā tūroro mate pukupuku waha kōpū, ko te ORR he 45.5% (5/11) me te 4 ngā tohu (36.4%) i tutuki i te PR me te 1 te tohu (9.1%) i tutuki i te CR. I kitea te mana whakahaere mate i roto i te 10/11 ngā tohu (90.9%), ā, ko te PFS toharite he 4.2 marama mō tēnei rōpū. I whaihia te tūroro CR i roto i te aroturukitanga roa, ā, ko te roanga o te CR me te PFS (i whakatauhia e Kaplan-Meier) he 24 wiki me te 36 wiki, ia. I muri i te werohanga GT101, ka tino whānui te tipu o te pūtau-T i roto i te toto ā-taha o ngā tūroro katoa, ko te Tmax toharite he 6.83 ngā rā, ā, ko te toharite he 15.9 ngā rā.
Ngā Whakatau: I roto i te rangahau Wāhanga 1 o te GT101, kāore i kitea he SAE me he DLT e pā ana ki te maimoatanga. I roto i ngā tūroro he pukupuku totoka kua horapa, kua tino rongoatia rānei i mua i te maimoatanga, i whakaatuhia e te GT101 he āhua haumaru e taea te whakahaere i raro i te tikanga maimoatanga o te lymphodepletion me te IL-2 horopeta nui me te āhua haumanu pai, inā koa i roto i te mate pukupuku waha whare tangata, me te ORR whakatenatena me te roa o te urupare pumau.
I tēnei wā, he maha tonu ngā whakamātautau haumanu o ngā hangarau hou hei ārai i te matepukupuku i Haina e rapu ana i ngā tūroro. Mēnā kei te hiahia koe ki te kōrero mō ngā rongoā me ngā hangarau hou, ka taea e koe te whakapā atu ki te Tari Ao o te Hōhipera Oncology Rohe Tonga o Beijing.
Tau Waea：4008803716
Email：myimmnet@163.com
Ngā Tohutoro
1.https://www.grit-bio.com/newsinfo/4620292.html
2.https://ascopubs.org/doi/10.1200/JCO.2024.42.16_suppl.2548
Wā tuku: Hakihea-20-2024